Monopar Therapeutics short interest in 2021
In 2021, Monopar Therapeutics's disclosed short interest ran from 0.21% of shares outstanding on 15 Jan 2021 to 0.22% on 31 Dec 2021, a change of +0.01 percentage points. The year's high was 0.77% on 15 Sep 2021 and its low 0.17% on 26 Feb 2021, averaging 0.43% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.90 days on 30 Jul 2021. Full history: Monopar Therapeutics.
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 0.21% (15 Jan 2021)
- End of year
- 0.22% (31 Dec 2021)
- Change
- +0.01 pp
- High
- 0.77% (15 Sep 2021)
- Low
- 0.17% (26 Feb 2021)
- Average
- 0.43%
- Highest days to cover
- 7.90 (30 Jul 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 0.21% | 1.00 | |
| 29 Jan 2021 | 0.21% | 1.00 | |
| 12 Feb 2021 | 0.24% | 1.00 | |
| 26 Feb 2021 | 0.17% | 1.00 | |
| 15 Mar 2021 | 0.17% | 1.00 | |
| 31 Mar 2021 | 0.21% | 1.00 | 10-K filed, results (8-K) |
| 15 Apr 2021 | 0.31% | 1.00 | |
| 30 Apr 2021 | 0.47% | 1.59 | |
| 14 May 2021 | 0.55% | 3.81 | 10-Q filed, results (8-K) |
| 28 May 2021 | 0.54% | 3.04 | |
| 15 Jun 2021 | 0.54% | 1.54 | |
| 30 Jun 2021 | 0.55% | 1.62 | |
| 15 Jul 2021 | 0.55% | 4.29 | |
| 30 Jul 2021 | 0.50% | 7.90 | |
| 13 Aug 2021 | 0.50% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 0.42% | 2.72 | |
| 15 Sep 2021 | 0.77% | 1.00 | |
| 30 Sep 2021 | 0.64% | 3.34 | |
| 15 Oct 2021 | 0.62% | 4.24 | |
| 29 Oct 2021 | 0.69% | 3.44 | |
| 15 Nov 2021 | 0.63% | 1.54 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 0.40% | 2.31 | |
| 15 Dec 2021 | 0.30% | 2.39 | |
| 31 Dec 2021 | 0.22% | 1.00 |
See also: Monopar Therapeutics's full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.